Jones RB - Search Results

1

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, Savage CO, Jayne DR. Jones RB, et al. Arthritis Rheum. 2009 Jul;60(7):2156-68. doi: 10.1002/art.24637. Arthritis Rheum. 2009. PMID: 19565480 Free article.

2

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?

Flossmann O, Jones RB, Jayne DR, Luqmani RA. Flossmann O, et al. Among authors: jones rb. Ann Rheum Dis. 2006 Jul;65(7):841-4. doi: 10.1136/ard.2005.048900. Ann Rheum Dis. 2006. PMID: 16769779 Free PMC article. Review.

3

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.

Smith KG, Jones RB, Burns SM, Jayne DR. Smith KG, et al. Among authors: jones rb. Arthritis Rheum. 2006 Sep;54(9):2970-82. doi: 10.1002/art.22046. Arthritis Rheum. 2006. PMID: 16947528 Free article. Clinical Trial.

4

Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production.

Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D, Pusey CD, Salama AD. Pepper RJ, et al. Among authors: jones rb. Rheumatology (Oxford). 2008 Jul;47(7):1104-5. doi: 10.1093/rheumatology/ken175. Epub 2008 May 20. Rheumatology (Oxford). 2008. PMID: 18492710 No abstract available.

5

Modification and validation of the Birmingham Vasculitis Activity Score (version 3).

Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA. Mukhtyar C, et al. Ann Rheum Dis. 2009 Dec;68(12):1827-32. doi: 10.1136/ard.2008.101279. Epub 2008 Dec 3. Ann Rheum Dis. 2009. PMID: 19054820

6

What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?

Jones RB, Walsh M, Smith KG. Jones RB, et al. Curr Opin Rheumatol. 2009 May;21(3):256-61. doi: 10.1097/bor.0b013e32832a0698. Curr Opin Rheumatol. 2009. PMID: 19399995 Review.

7

B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.

Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D. Martinez Del Pero M, et al. Among authors: jones rb. Clin Otolaryngol. 2009 Aug;34(4):328-35. doi: 10.1111/j.1749-4486.2009.01968.x. Clin Otolaryngol. 2009. PMID: 19673980

8

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus.

Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Catapano F, et al. Among authors: jones rb. Nephrol Dial Transplant. 2010 Nov;25(11):3586-92. doi: 10.1093/ndt/gfq256. Epub 2010 May 11. Nephrol Dial Transplant. 2010. PMID: 20466686

9

Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid.

Hiemstra TF, Jones RB, Jayne DR. Hiemstra TF, et al. Among authors: jones rb. Nephron Clin Pract. 2010;116(1):c1-10. doi: 10.1159/000314543. Epub 2010 May 12. Nephron Clin Pract. 2010. PMID: 20484933 Free article. Review.

10

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group. Jones RB, et al. N Engl J Med. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169. N Engl J Med. 2010. PMID: 20647198 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

864 results

Search Page